Mincey scores 27, UMass-Lowell knocks off UMass 96-83
Syria’s Bashar Al Assad is in Moscow: Source
Sasa Ciani scores 16 to help UIC secure 73-67 victory over Illinois StateZionist org preps list of foreign pro-Hamas students, hoping Trump will deport them
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenSyria’s ousted President, Bashar Al Assad, and members of his family arrived in Russia’s capital, Moscow, on Sunday, December 8, Russian news agency reported, citing a Kremlin source. “Assad, with his family, has arrived in Moscow. Russia, based on humanitarian considerations, has granted them asylum,” the source told TASS. According to the source, Moscow considers it necessary to resume negotiations on a settlement in Syria under the auspices of the UN. Асад с членами своей семьи прибыл в Москву, РФ предоставила им убежище, сообщил источник в Кремле: https://t.co/OdWi0dPeOk pic.twitter.com/fij1xkPSCb “The leaders of the armed Syrian opposition guaranteed the security of Russian military bases and diplomatic institutions in Syria,” the source added. On November 27, opposition armed groups launched a massive offensive against government forces in Aleppo and Idlib provinces. On December 7, Assad’s opponents successfully captured major cities including Aleppo, Deir ez-Zor, Daraa, Hama, and Homs. On Sunday morning, Assad left his post and the country following internal Syrian negotiations.Strictly fans left saying same thing as they spot Dianne Buswell's parents sobbing in audienceCapital project: plugging in profits from a big battery
The world is constantly changing, as man comes up with new inventions and projects. It is a need in us that constantly makes us try to improve life around us. But many changes have a risk attached. Computerisation has its risk whereupon it reduces the much important personal contact and human judgement. Black Knight test area (Image: David White) How often have you suffered the immortal phrase “computer says no” or the computer tells the non-thinking operator that you are not you. Here I want to look at some of the better inventions and developments that have come out of the Isle of Wight. A Carisbrooke resident by the name of John Dennett realised that shipwrecks off the Island had cost many a mariner's life, and having an interest in rockets and their various uses, came up with the idea of putting them to use to help rescue mariners from stricken ships. The Dennett rescue rocket (Image: David White) It was thus in 1832 that he developed the Dennett rescue rocket. The idea being the firing of the rocket to carry a rescue line to the ship, thereby forming a means of escape via a bosun's chair. This method lasted until the 1950s and went on to save many a life over the years. Sticking to the subject of rocket propulsion, in the mid 1950s, East Cowes company Saunders Roe, later to become Westland Aerospace, developed Black Knight, followed in the 1960s by Black Arrow. Hovercraft SRN1 (Image: David White) They were built at the East Cowes factory and tested at the top secret test site above the Needles. Many local people helped in the development, and during this time Britain become the leaders in space technology - even launching Prospero - one of the first satellites. It is still believed to be orbiting the earth today. The Britten-Norman Islander (Image: David White) Following a government decision in 1971 to cancel our space programme all our research was given to the USA to help further their space programme. This gave Britain the dubious title of being the only country to fully develop a space programme, then to fully cancel one. Not quite a rocket but another great engineering achievement to come out of the Island was the land speed record breaking Thrust 2. Designed by Isle of Wight engineer John Ackroyd, and built on a limited budget in a shed at Fishbourne, it achieved the land speed record for Britain in Black Rock, USA, in 1983 at a staggering 633mph. It held the record until 1997. Developed and built by Saunders Roe in East Cowes in the 1950s, the SRN1 was the world's first hovercraft. The brainchild of Christopher Cockerell, it introduced a new form of transport. Following a successful launch the continuing improved development introduced the giant SRN4 - a mainstay of transport across the English Channel, and SRN7 -a military version. Up until the present day a reliable service still operates from Ryde to Southsea. In air transport the Britten-Norman Islander proved among the most popular planes of modern aeronautics. Originally taking to the sky in 1965, it is still in production with over 1,300 built to date. It was designed and developed in Bembridge by John Britten and Desmond Norman. I have only scratched the surface of Island inventions and developments. Hopefully I will get the chance to cover more in future issues. Until then when bureaucrats and MPs at Westminster say of what importance is the Isle of Wight to Britain, perhaps they should be given a list of what a small Island has achieved to help shape our world. We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate. Last Updated: Are you sure you want to delete this comment?Miami quarterback Cam Ward has joined some elite company. In the Hurricanes 42-14 victory over Wake Forest, the senior quarterback broke Bernie Kosar's program record for passing yards in a single season. This feat saw Kosar himself take to X to celebrate Ward. Fans took to social media to praise Ward for breaking Kosar's record and hyped up his Heisman candidacy. Ward finished the day 27-of-38 for 280 yards with two touchdowns and one interception while also adding a touchdown on the ground. The Hurricanes produced 508 total offensive yards and limited the Demon Deacons to just 193. Jordan Lyle paced the rushing attack with seven carries for 115 yards and a touchdown. Jacolby George was the top receiver with seven catches for 91 yards and two touchdowns. Miami's improves to 10-1 with the victory and will head to Syracuse next week to close out the season. This redemption performance came after the team dropped its previous game against Georgia Tech, but the push for a conference championship and a berth in the College Football Playoff is officially back with the win over the Demon Deacons.
Florida: NATO Secretary-General Mark Rutte has met with President-elect Donald Trump in Palm Beach, Florida, NATO spokesperson Farah Dakhlallah announced on Saturday. Palm Beach, Florida is the location of Trump's Mar-a-Lago estate. The two leaders "discussed the range of global security issues facing the alliance," Dakhlallah said, without revealing further details. Trump is expected to push NATO members to pay more in defense expenditures in his second term, pushing for allies to spend 3% of their GDP on defense. In the past, Trump has also claimed that he "would encourage" Russia to "do whatever the hell they want" to countries which he deems are not paying their bills. Trump has also said he opposes further military aid to Ukraine, an idea which many European NATO members find disheartening. Trump has nominated Matthew Whitaker to be US ambassador to NATO. Whitaker is expected to pursue Trump's "America First" agenda during talks with NATO allies. Rutte wished to speak with Trump on growing Russia-North Korea ties Rutte had earlier expressed willingness to visit Trump at Mar-a-Lago after Trump was victorious over Kamala Harris in the November 5 US presidential election. Rutte had earlier said he wanted to speak with Trump on North Korea, Iran, China and Russia "working together, working together against Ukraine." "At the same time, Russia has to pay for this and one of the things they are doing is delivering technology to North Korea," Rutte said during a recent meeting of European leaders in Budapest. He said this development is threatening to the US and contintental Europe. "I look forward to sitting down with Donald Trump to discuss how we can face these threat collectively," the NATO chief had said.Cowboys Set to Host Bengals Under Open Roof After Falling Debris Thwarted That Plan Against Texans
FOXBOROUGH, Mass. (AP) — Following his team’s latest setback, a season-worst 40-7 loss to the Los Angeles Chargers, Patriots coach Jerod Mayo didn’t hold his tongue about what continue to be New England's most glaring deficiencies. “This is what I told the players, there’s really nothing good to take out of that game today. Just the lack of execution,” Mayo said Saturday to begin his postgame news conference. “We just didn’t play well enough in any phase of the game. No complementary football, and that’s what you get.” At 3-13 with a game to go, this has been a lost season for New England. And that frustration is showing in a locker room that has faith in its coach but also recognizes that major offseason changes are likely coming for a team that has failed to meet even modest expectations this season. “I don’t want to use the same excuse, everyone says, ‘Oh, it’s a young team,’” cornerback Jonathan Jones said. “But it’s just learning that everything’s not going to go your way. That’s in football, in life, how you respond to that adversity is what type of team you’re going to have.” Receiver Demario Douglas expects the roster to look much different next season. “I feel like my two years I’ve been losing, and I feel like it’s time to make a change,” Douglas said. “We’ve got some pieces, we’ll add more pieces next year, and I feel like we could come out and do something. I’m trying to be in the playoffs, I’m trying to go for a run and have a winning season. I’m just tired of losing for real.” What’s working The Patriots currently are in position to secure the No. 1 pick in the 2025 NFL draft. That could change with a game to go, but it's a valuable position for a team that appears set at quarterback with rookie Drake Maye and has several needs to fill. What needs help Turnovers continue to plague the Patriots. They had just one on Saturday, a fumble on a botched pitch by Maye. That’s at least one turnover in eight straight games for the rookie. Stock up Offensive lineman Cole Strange made his first start of the season a week after returning from injured reserve following offseason knee surgery. Strange, who played his first 27 NFL games at guard, started at center after Ben Brown was placed in IR with a concussion. Stock down Cole's presence didn't help the Patriots' struggling offensive line, which allowed four sacks and five quarterback hits on Maye. New England has allowed 51 sacks, the fifth most in the NFL. Injuries Maye was evaluated for a head injury in the first quarter but returned. CB Christian Gonzalez left the game with a concussion. Key number 1-6 — The Patriots' record at home this season. They are 2-14 at Gillette Stadium over the past two seasons. Next steps New England hosts AFC East champion Buffalo next weekend in its season finale. ___ AP NFL: https://apnews.com/hub/nfl Kyle Hightower, The Associated Press
No long queues as Nadra unveils self-service Kiosks for ID card renewalTejashwi Yadav, Sharad Pawar Back Mamata for I.N.D.I.A. Head